search
Back to results

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
REGN1193
Placebo
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Metformin monotherapy at a dose of ≥1000 mg/day (up to the maximum daily dose of 2550 mg per day) for ≥8 weeks prior to randomization
  2. Hemoglobin A1c value of ≥7.0% to ≤10.0%
  3. Fasting plasma glucose value ≥130 mg/dL and ≤240 mg/dL

Exclusion Criteria:

  1. Type 1 diabetes mellitus
  2. Use of insulin or oral or injectable antihyperglycemic medications during the 8 weeks prior to randomization
  3. A severe hypoglycemic event in the 6 months prior to randomization

Note: The eligibility criteria listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part A

Part B

Arm Description

Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.

Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.

Outcomes

Primary Outcome Measures

Incidence and severity of treatment emergent adverse events (TEAEs)

Secondary Outcome Measures

Pharmacodynamic profile of REGN1193 as measured by plasma glucose over time
Concentration of REGN1193 in serum over time

Full Information

First Posted
October 22, 2014
Last Updated
May 10, 2016
Sponsor
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT02284425
Brief Title
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Terminated
Study Start Date
October 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regeneron Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part A
Arm Type
Experimental
Arm Description
Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
Arm Title
Part B
Arm Type
Experimental
Arm Description
Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
Intervention Type
Drug
Intervention Name(s)
REGN1193
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Incidence and severity of treatment emergent adverse events (TEAEs)
Time Frame
Day 1 through Day 57
Secondary Outcome Measure Information:
Title
Pharmacodynamic profile of REGN1193 as measured by plasma glucose over time
Time Frame
Day 1 through Day 57
Title
Concentration of REGN1193 in serum over time
Time Frame
Day 1 through Day 57

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Metformin monotherapy at a dose of ≥1000 mg/day (up to the maximum daily dose of 2550 mg per day) for ≥8 weeks prior to randomization Hemoglobin A1c value of ≥7.0% to ≤10.0% Fasting plasma glucose value ≥130 mg/dL and ≤240 mg/dL Exclusion Criteria: Type 1 diabetes mellitus Use of insulin or oral or injectable antihyperglycemic medications during the 8 weeks prior to randomization A severe hypoglycemic event in the 6 months prior to randomization Note: The eligibility criteria listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trial Management
Organizational Affiliation
Regeneron Pharmaceuticals
Official's Role
Study Director
Facility Information:
City
Miami
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Knoxville
State/Province
Tennessee
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs